Company news
Aeolus Pharmaceuticals Inc news in 2017
Aeolus Pharmaceuticals Inc's news releases, calls and decks from 2017, newest first.
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150
September 25, 2017
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
September 21, 2017
Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
September 19, 2017
AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects
September 17, 2017
Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017
August 13, 2017
Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
June 8, 2017
Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017
May 15, 2017
Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification
March 23, 2017
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis
March 15, 2017
Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
February 22, 2017